676530-73-7

Upstream product

• 508-02-1 Oleanolic acid 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 676530-88-4 10-[5-acetoxy-6-acetoxymethyl-3-(2-azidomethyl-benzoyloxy)-4-(2,2-dimethyl-propionyloxy)-tetrahydro-pyran-2-yloxy]-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-2H-picene-4a-carboxylic acid 
• 676530-74-8 C₆₉H₉₃N₃O₁₂Si 

Relevant academic research and scientific papers

Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion Inhibitor: A promising strategy for discovering new antiviral therapeutics

Triterpene saponins are a major group of active components in natural products with nonspecific antiviral activities, while T20 peptide (enfuvirtide), which contains a helix zone-binding domain (HBD), is a gp41-specific HIV-1 fusion inhibitor. In this paper, we report the design, synthesis, and structure-activity relationship (SAR) of a group of hybrid molecules in which bioactive triterpene sapogenins were covalently attached to the HBD-containing peptides via click chemistry. We found that either the triterpenes or peptide part alone showed weak activity against HIV-1 Env-mediated cell-cell fusion, while the hybrids generated a strong cooperative effect. Among them, P26-BApc exhibited anti-HIV-1 activity against both T20-sensitive and -resistant HIV-1 strains and improved pharmacokinetic properties. These results suggest that this scaffold design is a promising strategy for developing new HIV-1 fusion inhibitors and possibly novel antiviral therapeutics against other viruses with class I fusion proteins.

Facile Synthesis of Ginsenoside Ro

Two concise synthetic routes, being different in the glycosylation sequence, toward ginsenoside Ro (1) are developed. These syntheses feature the elaboration of the glucuronide residue at a later stage via the TEMPO-mediated selective oxidation and the installation of AZMB as a benzoylic neighboring participating group capable of being selectively removed afterward.